Details

Autor(en) / Beteiligte

• Duman, Murat
• Şık, Nihan
• Tekşam, Özlem
• Akça, Halise
• Kurt, Funda
• Çağlar, Ayla Akca
• Yıldız, Leman Akcan
• Taşar, Medine Ayşin
• Fidancı, İlknur
• Yayla, Burcu Ceylan Cura
• Yılmaz, Durgül
• Güngör, Emre
• Demir, Şule
• Çokuğraş, Haluk
• Cebeci, Sinem Oral
• Önal, Pınar
• Saz, Eylem Ulaş
• Yurtseven, Ali
• Uysalol, Metin
• Yıldız, Raif
• Gümüş, Süheyla
• Bal, Alkan
• Bayturan, Semra Şen
• Zengin, Neslihan
• Atik, Sinem
• Çiftdoğan, Dilek Yılmaz
• Berksoy, Emel
• Çiçek, Alper
• Şahin, Sabiha
• Kızıl, Mahmut Can
• Kara, Yalçın
• Apa, Hurşit
• Ulusoy, Emel
• Kara, Aybüke Akaslan
• Yesil, Edanur
• Erdem, Meltem
• Turan, Caner
• Arslanoglu, Sertac
• Duyu, Muhterem
• Besli, Gulser Esen
• Arslan, Gazi
• Oflu, Ayşe Tolunay
• Çeleğen, Mehmet
• Buldu, Ebru
• Pişkin, İbrahim Etem
• Kardeş, Hakan
• Yılmaz, Hayri Levent
• Yıldızdaş, Dinçer
• Gökulu, Gamze
• Çay, Pınar
• Özer, Utku
• Güleryüz, Okşan Derinöz
• Çolak, Özlem
• Güneysu, Songül Tomar

Titel

COVID-19 Disease in Presenting to the Pediatric Emergency Department: A Multicenter Study of 8886 Cases

Ist Teil von

• The American journal of emergency medicine, 2022-09, Vol.59, p.133-140

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim was to evaluate the epidemiological, clinical, laboratory, and radiologic data of children with SARS-CoV-2 positivity by polymerase chain reaction (PCR) together with treatment strategies and clinical outcomes and to evaluate cases of multisystem inflammatory syndrome in children (MIS-C) in this population. This was a multicenter retrospective observational cohort study performed in the pediatric emergency departments of 19 tertiary hospitals. From March 11, 2020, to May 31, 2021, children who were diagnosed with confirmed nasopharyngeal/tracheal specimen SARS-CoV-2 PCR positivity or positivity for serum-specific antibodies against SARS-CoV-2 were included. Demographics, presence of chronic illness, symptoms, history of contact with SARS-CoV-2 PCR-positive individuals, laboratory and radiologic investigations, clinical severity, hospital admissions, and prognosis were recorded. A total of 8886 cases were included. While 8799 (99.0%) cases resulted in a diagnosis of SARS-CoV-2 with PCR positivity, 87 (1.0%) patients were diagnosed with MIS-C. Among SARS-CoV-2 PCR-positive patients, 51.0% were male and 8.5% had chronic illnesses. The median age was 11.6 years (IQR: 5.0–15.4) and 737 (8.4%) patients were aged <1 year. Of the patients, 15.5% were asymptomatic. The most common symptoms were fever (48.5%) and cough (30.7%) for all age groups. There was a decrease in the rate of fever as age increased (p < 0.001); the most common age group for this symptom was <1 year with the rate of 69.6%. There was known contact with a SARS-CoV-2 PCR-positive individual in 67.3% of the cases, with household contacts in 71.3% of those cases. In terms of clinical severity, 83 (0.9%) patients were in the severe-critical group. There was hospital admission in 1269 (14.4%) cases, with 106 (1.2%) of those patients being admitted to the pediatric intensive care unit (PICU). Among patients with MIS-C, 60.9% were male and the median age was 6.4 years (IQR: 3.9–10.4). Twelve (13.7%) patients presented with shock. There was hospital admission in 89.7% of these cases, with 29.9% of the patients with MIS-C being admitted to the PICU. Most SARS-CoV-2 PCR-positive patients presented with a mild clinical course. Although rare, MIS-C emerges as a serious consequence with frequent PICU admission. Further understanding of the characteristics of COVID-19 disease could provide insights and guide the development of therapeutic strategies for target groups.